Completed OBSERVATIONAL NCT02447627

Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

A Study of Methodologies to Measure Blood Flow and Oxygenation as Potential Biomarkers in Adults With Sickle Cell Disease

Sponsor: Bioverativ Therapeutics Inc.

Conditions Healthy Sickle Cell Disease

Updated 11 times since 2017 Last updated: Dec 16, 2020 Started: Jun 30, 2015 Primary completion: Oct 31, 2016 Completion: Oct 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02447627, this observational or N/A phase trial focuses on Healthy and Sickle Cell Disease and remains completed. Sponsored by Bioverativ Therapeutics Inc., it has been updated 11 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2020 — Jan 2021 [monthly]

Completed

▶ Show 6 earlier versions

Jun 2018 — Nov 2020 [monthly]

Completed
May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Sep 2017 — Apr 2018 [monthly]

Completed NA
Aug 2017 — Sep 2017 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Jun 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bioverativ Therapeutics Inc.

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Detroit, United States